Arabic Arabic English English French French German German
dark

Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 Mutations

Tempus, a leader in artificial intelligence and precision medicine, today announced the commencement of an open label phase II study, in collaboration with GlaxoSmithKline (GSK) to evaluate the efficacy and safety of ZEJULA (niraparib), a poly (ADP-ribose) polymerase (PARP) inhibitor used for patients with advanced or metastatic solid tumors and a germline or somatic PALB2 mutation. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board

Next Post

UNIST Partners with Yonsei University Health System to Empower Smart Healthcare

Related Posts
Total
0
Share